Apex Welcomes Tom Zoda, Ph.D. to its Executive Leadership Team
Bringing almost 30 years of experience in the pharmaceutical and clinical trials industry, Tom Zoda, Ph.D. has joined Apex Innovative Sciences as Chief Operating Officer. In his role as COO, Dr. Zoda will work with the executive team to develop and implement strategies to grow Apex as a market leader in the Phase I-III clinical trials space.
Prior to joining Apex, Dr. Zoda served as the head of Syneos Health’s CNS Business Unit, overseeing all central nervous system trials globally. He was the head of global neurology and psychiatry clinical development for INC Research, later known as Syneos Health, where he was instrumental in growing the franchise from a small group of <200 people to over 1,600 professionals worldwide at its peak. He assumed leadership of the CNS group in 2015. Before joining INC Research, Dr. Zoda worked for PPD for more than a decade, finishing his time with the company as executive director for global strategic development, CNS. He previously also worked for Tanox Biosystems, overseeing the development of therapeutic antibodies and vaccines for the treatment of allergy. Dr. Zoda received his Ph.D. in Microbiology from the University of Texas Health Science Center in San Antonio and completed his post-doctoral work at the Geisel School of Medicine at Dartmouth.
On joining Apex, Dr. Zoda states, “Apex is a leader in the CNS and clinical pharmacology space with unique resources to offer sponsors and CROs, including a wealth of expertise in complex protocols involving sophisticated technologies. I am very happy to join the Apex team and look forward to applying my skillset across company operations.”
CEO, Dr. Howard Hassman, and Chief Clinical Officer, Dr. David Walling, agree that “As Apex faces the challenges and opportunities of an evolving industry, Tom’s outstanding experience in drug development and strategic leadership are a natural fit. We’ve both known Tom for many years, and we are confident that his experience leading large organizations will benefit our stakeholder community.”
About Apex Innovative Sciences
A global provider of clinical development and site services, Apex represents the consolidation of core businesses including CNS Research and Hassman Research Institute, industry-leading sites providing high quality study conduct for a wide range of Phase I-IV trials in healthy subjects, patient populations, and special populations. Apex prides itself on delivering scientific, technological, and clinical excellence at the speed needed to provide optimal value to clients. Apex’s expertise in program planning and protocol development helps sponsors reduce development costs and de-risk drug development. For more information, please visit: www.apexsci.com
Bobbie Theodore, M.S.
VP, Sponsor Relations/BD